Matthew Joshua Frank, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Frank’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A124604 · Current
Licensed to practise in California · since 2013 · expires 2028-08-31 · David Geffen School of Medicine at UCLA.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$40,031
Medicare paid this office $40,031 for 88 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 63 | $21,052 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $8,410 | $106 |
| Long return visit (40+ min) | 22 | $7,182 | $163 |
Who their Medicare patients are
88 Original Medicare patients in 2024. Average age 71 · Women 51% · Also on Medicaid 19% · Health risk score 3.00. Sicker patients than 9 in 10 peers; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 65% · Coronary heart disease 28% · Chronic kidney disease 25% · Atrial fibrillation 24% · Depression 23% · Dementia 19% · Diabetes 16% · COPD 15% · Cancer 14%.
The office billed $116,393, Medicare allowed $52,339 and paid $40,031; for 318 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 88 | 318 | 71 | 3.00 | $116,393 | $40,031 |
| 2023 | 91 | 386 | 69 | 2.96 | $143,943 | $48,088 |
| 2022 | 75 | 352 | 70 | 2.60 | $135,225 | $39,678 |
| 2021 | 76 | 319 | 69 | 2.83 | $113,429 | $33,378 |
| 2020 | 53 | 198 | 70 | 2.92 | $67,821 | $18,161 |
| 2019 | 38 | 144 | 68 | 2.47 | $67,766 | $13,741 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 68 | $27,810 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $14,700 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,399 | $160 |
2022: 4 services
| Long return visit (40+ min) | 52 | $18,560 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $14,465 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,164 | $180 |
| New patient visit (60+ min) | 12 | $2,106 | $175 |
2021: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $15,019 | $94 |
| Long return visit (40+ min) | 28 | $6,262 | $125 |
| Return visit (30+ min) | 29 | $4,859 | $81 |
| New patient visit (60+ min) | 16 | $2,722 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,218 | $171 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,287 | $99 |
2020: 3 services
| Return visit (30+ min) | 29 | $6,178 | $71 |
| Long return visit (40+ min) | 26 | $3,939 | $104 |
| New patient visit (60+ min) | 12 | $1,764 | $147 |
2019: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $6,786 | $93 |
| Long return visit (40+ min) | 17 | $2,686 | $99 |
| Return visit (30+ min) | 13 | $2,192 | $71 |
Medicaid work
$3,136 in 2024
Medicaid paid $3,136 for 28 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 28 | $3,136 |
| 2024 | 28 | 1 | 13 | $3,136 |
| 2023 | 47 | 1 | 21 | $3,280 |
| 2022 | 38 | 1 | 17 | $2,198 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 47 | $3,280 |
2022
| Long return visit (40+ min) | 38 | $2,198 |
Drugs they prescribed that Part D paid
$144,713
Pharmacies billed $144,713 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
339 generic and 29 brand-name prescriptions · $144,713 in drug cost · 119 antibiotic prescriptions to 28 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Atovaquone | 11 | $5,597 | $509 |
| Acyclovir | 83 | $2,155 | $26 |
| Sulfamethoxazole-Trimethoprim | 100 | $847 | $8 |
| Ondansetron | 26 | $331 | $13 |
| Lorazepam | 20 | $163 | $8 |
See all 6 drugs
| Atovaquone | 11 | $5,597 | $509 |
| Acyclovir | 83 | $2,155 | $26 |
| Sulfamethoxazole-Trimethoprim | 100 | $847 | $8 |
| Ondansetron | 26 | $331 | $13 |
| Lorazepam | 20 | $163 | $8 |
| Allopurinol | 21 | $84 | $4 |
Year by year
| 2024 | 368 | 58 | None | 8% | $144,713 |
| 2023 | 190 | 31 | None | None | $35,111 |
| 2022 | 310 | 46 | None | 5% | $60,481 |
| 2021 | 344 | 51 | None | 9% | $109,226 |
| 2020 | 241 | 31 | None | 13% | $270,655 |
| 2019 | 48 | None | 0% (0) | 23% | $103,170 |
| 2013 | 127 | 21 | None | None | $3,802 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Acyclovir | 54 | $2,276 | $42 |
| Sulfamethoxazole-Trimethoprim | 37 | $424 | $11 |
| Pantoprazole | 11 | $293 | $27 |
2022: 7 drugs
| Posaconazole | 14 | $39,503 | $2,822 |
| Atovaquone | 12 | $6,480 | $540 |
| Acyclovir | 76 | $3,198 | $42 |
| Entecavir | 15 | $843 | $56 |
| Sulfamethoxazole-Trimethoprim | 87 | $827 | $10 |
| Ondansetron | 11 | $84 | $8 |
| Allopurinol | 16 | $48 | $3 |
2021: 9 drugs
| Posaconazole | 11 | $26,196 | $2,381 |
| Atovaquone | 19 | $11,676 | $615 |
| Eliquis | 13 | $6,913 | $532 |
| Acyclovir | 51 | $1,954 | $38 |
| Sulfamethoxazole-Trimethoprim | 86 | $597 | $7 |
| Ondansetron | 22 | $211 | $10 |
| Lorazepam | 20 | $113 | $6 |
| Pantoprazole | 12 | $107 | $9 |
| Allopurinol | 14 | $62 | $4 |
2020: 8 drugs
| Posaconazole | 12 | $42,342 | $3,528 |
| Atovaquone | 28 | $24,179 | $864 |
| Acyclovir | 15 | $742 | $49 |
| Sulfamethoxazole-Trimethoprim | 36 | $324 | $9 |
| Ondansetron | 20 | $259 | $13 |
| Prochlorperazine Maleate | 15 | $234 | $16 |
| Levofloxacin | 13 | $169 | $13 |
| Lorazepam | 15 | $88 | $6 |
2013: 4 drugs
| Levothyroxine | 14 | $126 | $9 |
| Simvastatin | 15 | $113 | $8 |
| Lisinopril | 13 | $79 | $6 |
| Omeprazole | 11 | $75 | $7 |
Money from drug and device companies
$21,360 in 2025
| 2025 | 5 | 34 | $8,580 | $21,360 |
| 2024 | 4 | 34 | $9,600 | $24,766 |
| 2023 | 5 | 13 | $8,570 | $9,798 |
| 2022 | 2 | 4 | None | $222 |
| 2021 | 2 | 2 | $2,750 | $2,775 |
| 2020 | 1 | 1 | $4,530 | $4,530 |
| 2019 | 1 | 1 | None | $96 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Yescarta | $15,649 | 20 payments
|
| Adaptive Biotechnologies | Clonoseq | $5,071 | 7 payments
|
| Sobi | Gamifant | $586 | 5 payments
|
| Boston Scientific | Ranger | $27 | 1 payment
|
| Incyte | Niktimvo | $27 | 1 payment
|
See all 34 published payments
| Gilead Sciences | Travel · 2025-12-12 | None | $1,184 |
| Sobi | Meals · 2025-12-06 | Gamifant | $43 |
| Gilead Sciences | Meals · 2025-11-05 | None | $38 |
| Gilead Sciences | Meals · 2025-11-05 | None | $37 |
| Gilead Sciences | Meals · 2025-11-05 | None | $33 |
| Gilead Sciences | Meals · 2025-11-05 | None | $32 |
| Gilead Sciences | Meals · 2025-11-05 | None | $20 |
| Gilead Sciences | Meals · 2025-11-05 | Yescarta | $4 |
| Gilead Sciences | Meals · 2025-11-04 | Yescarta | $42 |
| Gilead Sciences | Meals · 2025-11-02 | Yescarta | $51 |
| Gilead Sciences | Travel · 2025-10-09 | None | $90 |
| Gilead Sciences | Meals · 2025-10-09 | None | $105 |
| Sobi | Meals · 2025-09-13 | Gamifant | $33 |
| Sobi | Meals · 2025-09-13 | Gamifant | $141 |
| Sobi | Travel · 2025-09-13 | Gamifant | $219 |
| Gilead Sciences | Travel · 2025-08-23 | None | $103 |
| Gilead Sciences | Travel · 2025-08-21 | None | $96 |
| Gilead Sciences | Travel · 2025-08-21 | None | $16 |
| Gilead Sciences | Travel · 2025-08-21 | None | $16 |
| Gilead Sciences | Meals · 2025-08-20 | Yescarta | $89 |
| Gilead Sciences | Travel · 2025-08-17 | None | $9,289 |
| Boston Scientific | Meals · 2025-08-07 | Ranger | $27 |
| Gilead Sciences | Consulting · 2025-07-04 | Yescarta | $4,180 |
| Gilead Sciences | Meals · 2025-06-20 | Yescarta | $104 |
| Sobi | Meals · 2025-02-13 | Gamifant | $149 |
| Gilead Sciences | Meals · 2025-02-12 | Yescarta | $121 |
| Incyte | Meals · 2025-01-28 | Niktimvo | $27 |
| Adaptive Biotechnologies | Travel · 2025-01-23 | Clonoseq | $233 |
| Adaptive Biotechnologies | Travel · 2025-01-23 | Clonoseq | $152 |
| Adaptive Biotechnologies | Travel · 2025-01-23 | Clonoseq | $222 |
| Adaptive Biotechnologies | Consulting · 2025-01-23 | Clonoseq | $4,400 |
| Adaptive Biotechnologies | Meals · 2025-01-13 | Clonoseq | $2 |
| Adaptive Biotechnologies | Meals · 2025-01-13 | Clonoseq | $18 |
| Adaptive Biotechnologies | Meals · 2025-01-13 | Clonoseq | $44 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $24,766
| Gilead Sciences | None | $12,902 | 4 payments
|
| ADC Therapeutics America | None | $10,988 | 8 payments
|
| Boston Scientific | Eluvia | $577 | 19 payments
|
| Sobi | Gamifant | $298 | 3 payments
|
2023: $9,798
| Gilead Sciences | Yescarta | $6,113 | 3 payments
|
| Kite Pharma | Yescarta | $3,547 | 7 payments
|
| Janssen Biotech | Carvykti | $73 | 1 payment
|
| Celgene | None | $48 | 1 payment
|
| Boston Scientific | Eluvia | $17 | 1 payment
|
2022: $222
| Kite Pharma | None | $125 | 1 payment
|
| Gilead Sciences | None | $97 | 3 payments
|
2021: $2,775
| Adaptive Biotechnologies | Clonoseq | $2,750 | 1 payment
|
| CSL Behring | Hizentra | $25 | 1 payment
|
2020: $4,530
| Kite Pharma | Yescarta | $4,530 | 1 payment
|
2019: $96
| Adaptive Biotechnologies | Clonoseq | $96 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kite Pharma, Inc. · A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma · 2025 | Their institution | $567,791 |
| Kite Pharma, Inc. · A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma · 2024 | Their institution | $121,133 |
| Kite Pharma, Inc. · A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma · 2023 | Their institution | $108,999 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285929232
- Licence
- CA A124604California A124604: Current · expires 2028-08-31
- Trained
- University of California, Geffen School of Medicine, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-06-16
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 330 Brookline Ave # 300, Boston, MA, 02215 · 269 Campus Dr, Stanford, CA, 94305